Our aim is to understand how nutrition and metabolism influence the ability to respond to events occurring during the lifecourse. To date this has included studies investigating the response of adults to a high-fat meal, the role of maternal diet during pregnancy, and the effect of nutrients in patients with chronic diseases such as type 2 diabetes, fatty liver disease and vascular disease. The scope of our work covers the full spectrum of nutrition and metabolism research, from looking at changes occurring at a cellular and epigenetic level, through to monitoring effects on clinical outcomes and even behaviour.
Researchers in our group work closely with the National Institute for Health Research (NIHR) Southampton Biomedical Research Centre at University Hospital Southampton, on studies carried out in both healthy volunteers and in patients recruited from clinics. (More detail below)
Through our work, we strive to optimize growth and development, improve health and lower disease risk, and to improve the evidence base needed for translation into public health and clinical practice. Our staff also have key roles in the education of undergraduates and postgraduates on courses aligned with our research including the MSc in Public Health Nutrition and the MSc in Diabetes Best Practice
Within the Southampton National Institute for Health Research (NIHR) Biomedical Research Centre at University Hospital Southampton, the focus of our internationally renowned research is:
These conditions frequently occur together in patients and besides placing a burden on health care resources within the NHS, cause considerable physical ill-health and psychological distress to affected individuals.
We recruit patients from clinics across the region to participate in proof of concept clinical trials that are focussed on:
We have undertaken the largest ever omega-3 fatty acid trial for treating early liver disease in NAFLD and the results of this trial provided key information that was incorporated into the first National Institute for Care Excellence (NICE) Clinical Guidelines for the management of NAFLD. Currently, we are undertaking a world-leading proof of concept trial to test whether changing the bacteria in our intestines with a synbiotic treatment improves liver disease and risk factors for metabolic and vascular disease in patients with NAFLD [INSYTE – INvestigation of SYnbiotic TreatmEnt in Non Alcoholic Fatty Liver Disease (NAFLD)]. The results of INSYTE will be available in 2018.